By Peter Loftus
March 21, 2021 8:00 am ET

Covid-19 vaccine manufacturers are ramping up production, churning out far more doses a week than earlier in the year, progress that is accelerating mass vaccination campaigns in the U.S.

After a slow start, Pfizer Inc., its partner BioNTech SE and Moderna Inc. have raised output by gaining experience, scaling up production lines and taking other steps like making certain raw materials on their own.

Pfizer figured out how to stretch scarce supplies of special filters needed for the vaccine production process by recycling them. Moderna shortened the time it needed to inspect and package newly manufactured vials of its vaccine.

The companies—along with Johnson & Johnson, which recently launched a Covid-19 vaccine—also are teaming up with other firms to further increase production.

In addition, the U.S. government has helped vaccine makers access supplies under the Defense Production Act, suppliers and government officials say. The Biden administration this month said it used the act to provide $105 million in funding to help Merck & Co. make doses of J&J’s Covid-19 vaccine and to expedite materials used in its production.

Both the production and administration of shots have picked up in recent weeks, however. Now, some 2.5 million people in the U.S. are vaccinated daily on average, up from about 500,000 in early January, though many who want a vaccine still can’t get it.

The increased output should be enough to fully vaccinate 76 million people in the U.S. in March, another 75 million in April and then 89 million more in May, according to estimates from Evercore ISI analysts. The Pfizer-BioNTech and Moderna vaccines require two doses.

By midsummer, 75% of Americans 12 years old and above should be vaccinated, according to Morgan Stanley. 

https://www.wsj.com/articles/covid-19-vaccine-manufacturing-in-u-s-races-ahead-11616328001?mod=hp_lead_pos2



1. 미국 백신 제약사들, 경험 누적되면서 가속도가 붙어
3월 1달동안 1억3천2백만 회 백신 생산함

2. 미국 정부는 전시생산법을 가동해
백신 생산에 매진, 3월에 7천5백만명 접종 완료함

3. 4월에는 7천5벡만명 추가로 접종 완료,
5월엔 8천9백만명 추가로 접종 완료할 계획

4. 현재는 12세-18세 접종 개발중. 여름 중순까지는
12세 이상 인구의 75% 접종 완료할 계획

5. 화이자, 모더나, 죤슨앤죤슨 백신,
미국인 접종 끝날 때까지 수출 금지령 내림

6. 아스트라 백신은 하자가 많아 미국 승인 안남
그러나 상당량을 선구입했기때문에 다른 나라들에 무상 제공함


(한줄요약) 미국은 실질적으로 5월에 마스크 벗고 일상으로 돌아가고, 한국은 마스크와 집회금지, 거리두기로 버텨야 함